153  0 Kommentare Quest Diagnostics and Ultima Collaborate to Scale Ultima’s Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing

The collaboration aims to improve patient access, affordability and outcomes by broadening the use of highly accurate, cost-efficient and high-volume whole genome sequencing for fast-growth areas, such as solid-tumor minimal residual disease (MRD) testing. Quest intends to deploy the Ultima technology for the possible development of lab-developed tests involving its Haystack solid-tumor MRD technology for future clinical and biopharmaceutical MRD applications, supplementing its current whole exome sequencing approach, as well as for certain future whole genome testing applications, such as rare disease detection in pediatric patients.

Ultima recently unveiled its platform technology, a new sequencing architecture that supports sequencing an entire genome for $100. At an event in December 2023, the Company previewed its first commercial system to use this new architecture, the UG 100 System, to a group of leaders across the genomics field. In addition to lower costs, the technology is also unique for its high sensitivity for detecting rare cancer-related gene variants, particularly changes in DNA base pairs called single nucleotide variants (SNVs).

The collaboration will leverage Quest's expertise and scale in oncology, genomics and pathology and national scale in tumor biopsy and blood specimen collection. Quest provides comprehensive oncology services, spanning genetic risk assessment, cancer diagnostics and treatment monitoring, to marquee health systems and other providers in the United States. The company’s approximately 400 AmeriPath pathologists provide tumor biopsy diagnostic services while its 7,000 patient access sites nationwide provide blood draws.

Lesen Sie auch

Im Fokus

2 Gesundheits- und Wachstumswerte mit attraktiver Bewertung

gestern 16:00

Ihre wichtigsten Termine

Alle Analysten-Augen auf: Biontech, Boeing, Zalando, Fresenius und Hensoldt AG

17.05.24, 04:30

Google, Meta abgestoßen

Hedgefonds-Star Tepper setzt auf China und spekuliert auf Rebound von Verlierern

16.05.24, 12:30

Hedgefonds-Legende

Michael Burry trennt sich von Alphabet & Amazon – und wettet auf Alibaba & Gold!

16.05.24, 10:29

“We are delighted to collaborate with the world’s leading diagnostics information services provider to deploy our technology toward lab-developed tests for applications benefiting from insights from whole genome sequencing,” said Gilad Almogy, Ultima Genomics CEO. “Ultima’s technology was designed for applications requiring greater sequencing depth, breadth, or frequency and both MRD testing and whole genome sequencing are premier examples of these. Our unique advantages in SNV detection, combined with greater sequencing depth at lower cost can be transformational for oncology applications and MRD, as well as for cell-free DNA applications and applications with challenging samples. The collaboration with Quest emphasizes our focus on enabling the leading organizations that will help us scale our technology and, most importantly, benefit patients and providers.”